Back
  1. Generation of iPSCs for Rare Diseases

Generation of iPSCs for Rare Diseases

Janine Petters Chiara Cimmaruta Katharina Iwanov ML Chang Christin Völkner G Knuebel HM Escobar Moritz J Frech, PhD Andreas Hermann, MD Prof. Arndt Rolfs, MD Jan Lukas, PhD
January 27, 2020

Generation of induced pluripotent stem cell lines AKOSi002-A and AKOSi003-A from symptomatic female adults with Wilson disease

Induced pluripotent stem cells (iPSCs) represent excellent in vitro models to study rare diseases and perform high-throughput drug screening. CENTOGENE has established iPSC technology for rare monogenetic diseases in its Rostock headquarters based on patient-derived fibroblasts. Further advancements in this process is an ambitious task, which will be facilitated by close collaboration with local and global academic partners, as exemplified in a recent paper published in Stem Cell Research.